The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform
Azra Raza - One of the best experts on this subject based on the ideXlab platform.
-
Prognosis in myelodysplastic syndromes: Are the new Classifications useful?
Current Hematologic Malignancy Reports, 2008Co-Authors: Naomi Galili, Azra RazaAbstract:Increased understanding of the biologic and clinical parameters that define subgroups of myelodysplastic syndromes has led to continuing refinement of Classification strategies for diagnostic and prognostic use. The French-American-British Classification, based primarily on morphology, was modified by the World Health Organization system to include the negative impact of multilineage dysplasias and higher blast counts. In addition, this system identifies a distinct clinical subgroup characterized by an isolated chromosome 5 deletion. The International Prognostic Scoring System was created to calculate prognosis, risk of transformation to acute myeloid leukemia, and median survival times. However, therapeutic decisions cannot be solely guided by these systems, and the clinician must decide whether the intent is curative or palliative. Clinical symptoms and degree of transfusion dependency will dictate the degree of therapeutic intervention.
Laurent Degos - One of the best experts on this subject based on the ideXlab platform.
-
Results of All-Trans Retinoic Acid Treatment in Acute Promyelocytic Leukemia (European Experience)
Acute Leukemias VI, 1997Co-Authors: Laurent Degos, Pierre FenauxAbstract:Acute promyelocytic leukemia (APL) is a specific subtype of acute myeloid leukemia (AML) in the French-American-British Classification of AML[1], characterized by the morphology of blast cells (M3), the t(15;17) translocation which fuses the PML gene on chromosome 15 to the retinoic acid receptor alpha (RARα) gene on chromosome 17 [2], and by a coagulopathy combining disseminated intravascular coagulation (DIC), fibrinolysis, and proteolysis [3]. Intensive chemotherapy, including anthracycline was the most effective treatment of APL [4] with a high mortality due to the exacerbation of coagulopathy.
-
Treatment of acute promyelocytic leukemia with all- trans retinoic acid
Leukemia Research, 1991Co-Authors: Pierre Fenaux, Laurent DegosAbstract:Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia (AML) characterized by the morphology of blast cells (M3 in the French American British Classification of AML) [1 2], the t [15 17] translocation [3] which fuses the promyelocytic leukemia (PML) gene on chromosome 15 to the retinoic acid receptor (RARα) α gene on chromosome 17 [4 5], and by a coagulopathy combining disseminated intravascular coagulation (DIC) and fibrinolysis [6 8]. Until recently, intensive chemotherapy, usually combining an anthracycline and cytosine arabinoside (AraC) was the only effective treatment of APL [8-22].
-
Treatment of acute promyelocytic leukemia with all-rans retinoic acid
Leukemia Research, 1991Co-Authors: Pierre Fenaux, Laurent DegosAbstract:Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia (AML) characterized by the morphology of blast cells (M3 in the French American British Classification of AML) [1 2], the t [15 17] translocation [3] which fuses the promyelocytic leukemia (PML) gene on chromosome 15 to the retinoic acid receptor (RARα) α gene on chromosome 17 [4 5], and by a coagulopathy combining disseminated intravascular coagulation (DIC) and fibrinolysis [6 8]. Until recently, intensive chemotherapy, usually combining an anthracycline and cytosine arabinoside (AraC) was the only effective treatment of APL [8-22].
Pierre Fenaux - One of the best experts on this subject based on the ideXlab platform.
-
Results of All-Trans Retinoic Acid Treatment in Acute Promyelocytic Leukemia (European Experience)
Acute Leukemias VI, 1997Co-Authors: Laurent Degos, Pierre FenauxAbstract:Acute promyelocytic leukemia (APL) is a specific subtype of acute myeloid leukemia (AML) in the French-American-British Classification of AML[1], characterized by the morphology of blast cells (M3), the t(15;17) translocation which fuses the PML gene on chromosome 15 to the retinoic acid receptor alpha (RARα) gene on chromosome 17 [2], and by a coagulopathy combining disseminated intravascular coagulation (DIC), fibrinolysis, and proteolysis [3]. Intensive chemotherapy, including anthracycline was the most effective treatment of APL [4] with a high mortality due to the exacerbation of coagulopathy.
-
Treatment of acute promyelocytic leukemia with all- trans retinoic acid
Leukemia Research, 1991Co-Authors: Pierre Fenaux, Laurent DegosAbstract:Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia (AML) characterized by the morphology of blast cells (M3 in the French American British Classification of AML) [1 2], the t [15 17] translocation [3] which fuses the promyelocytic leukemia (PML) gene on chromosome 15 to the retinoic acid receptor (RARα) α gene on chromosome 17 [4 5], and by a coagulopathy combining disseminated intravascular coagulation (DIC) and fibrinolysis [6 8]. Until recently, intensive chemotherapy, usually combining an anthracycline and cytosine arabinoside (AraC) was the only effective treatment of APL [8-22].
-
Treatment of acute promyelocytic leukemia with all-rans retinoic acid
Leukemia Research, 1991Co-Authors: Pierre Fenaux, Laurent DegosAbstract:Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia (AML) characterized by the morphology of blast cells (M3 in the French American British Classification of AML) [1 2], the t [15 17] translocation [3] which fuses the promyelocytic leukemia (PML) gene on chromosome 15 to the retinoic acid receptor (RARα) α gene on chromosome 17 [4 5], and by a coagulopathy combining disseminated intravascular coagulation (DIC) and fibrinolysis [6 8]. Until recently, intensive chemotherapy, usually combining an anthracycline and cytosine arabinoside (AraC) was the only effective treatment of APL [8-22].
Riaz Shah Ss - One of the best experts on this subject based on the ideXlab platform.
-
Clinicopathological analysis of myelodysplastic syndrome according to French-American-British Classification.
Jcpsp-journal of The College of Physicians and Surgeons Pakistan, 2010Co-Authors: Ehsan A, Mona Aziz, Arif S, Asif Mj, Tooba Ammar, Riaz Shah SsAbstract:Objective: To evaluate the age of onset, gender ratio, clinical presentation of Myelodysplastic syndrome patients, and to classify these patients according to French-American-British Classification on the basis of morphological features in blood and bone marrow. Study Design: A case series.
Naomi Galili - One of the best experts on this subject based on the ideXlab platform.
-
Prognosis in myelodysplastic syndromes: Are the new Classifications useful?
Current Hematologic Malignancy Reports, 2008Co-Authors: Naomi Galili, Azra RazaAbstract:Increased understanding of the biologic and clinical parameters that define subgroups of myelodysplastic syndromes has led to continuing refinement of Classification strategies for diagnostic and prognostic use. The French-American-British Classification, based primarily on morphology, was modified by the World Health Organization system to include the negative impact of multilineage dysplasias and higher blast counts. In addition, this system identifies a distinct clinical subgroup characterized by an isolated chromosome 5 deletion. The International Prognostic Scoring System was created to calculate prognosis, risk of transformation to acute myeloid leukemia, and median survival times. However, therapeutic decisions cannot be solely guided by these systems, and the clinician must decide whether the intent is curative or palliative. Clinical symptoms and degree of transfusion dependency will dictate the degree of therapeutic intervention.